Bleb analysis and short-term results of biodegradable collagen matrix-augmented ahmed glaucoma valve implantation: 6-month follow-up

Seungsoo Rho, Youngje Sung, Kyoung Tak Ma, Sae Heun Rho, Chan Yun Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

PURPOSE. To evaluate the short-term efficacy of a biodegradable collagen matrix (BCM) as an adjuvant for Ahmed valve implantation surgery to prevent the hypertensive phase. METHODS. This prospective study included 43 refractory glaucoma eyes, all followed for 6 months. Refractory glaucoma was defined as an IOP higher than 20 mm Hg with antiglaucoma eye drops without previous glaucoma surgery. Conventional method was performed in 21 eyes and BCM-augmented Ahmed valve implantation (BAAVI) in 22 eyes. In the BAAVI group, a 10 × 10 × 2-mm BCM was sutured on an Ahmed glaucoma valve FP7 model. Complete success was defined as an IOP of 21 mm Hg or lower (target IOP 1) or 17 mm Hg or lower (target IOP 2) without antiglaucoma medications and qualified success as an IOP of 21 mm Hg or lower with or without medications. Maximal bleb thickness was measured using anterior segment optical coherence tomography images. RESULTS. The preoperative IOPs and numbers of preoperative antiglaucoma medications were similar for both groups. Complete target IOP 1 success rates were 38.1% and 86.4%, complete target IOP 2 success rates were 19.0% and 59.1%, and qualified success rates were 52.4% and 90.9% in the conventional and BAAVI groups, respectively (P = 0.05). The hypertensive phase rate was lower in the BAAVI group (4.5% vs. 47.6%, P = 0.002). Maximal bleb thickness was increased in the BAAVI group on postoperative days 30 and 180 (P = 0.05). CONCLUSIONS. Success rates were higher in the BAAVI group than in the conventional group with the change of bleb morphology. Furthermore, use of BCM significantly decreased the need for antiglaucoma medications for at least 6 months postoperatively.

Original languageEnglish
Article numberA023
Pages (from-to)5896-5903
Number of pages8
JournalInvestigative Ophthalmology and Visual Science
Volume56
Issue number10
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Blister
Glaucoma
Collagen
Ophthalmic Solutions
Optical Coherence Tomography
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

@article{308297178be0423f928f23d69c62cc39,
title = "Bleb analysis and short-term results of biodegradable collagen matrix-augmented ahmed glaucoma valve implantation: 6-month follow-up",
abstract = "PURPOSE. To evaluate the short-term efficacy of a biodegradable collagen matrix (BCM) as an adjuvant for Ahmed valve implantation surgery to prevent the hypertensive phase. METHODS. This prospective study included 43 refractory glaucoma eyes, all followed for 6 months. Refractory glaucoma was defined as an IOP higher than 20 mm Hg with antiglaucoma eye drops without previous glaucoma surgery. Conventional method was performed in 21 eyes and BCM-augmented Ahmed valve implantation (BAAVI) in 22 eyes. In the BAAVI group, a 10 × 10 × 2-mm BCM was sutured on an Ahmed glaucoma valve FP7 model. Complete success was defined as an IOP of 21 mm Hg or lower (target IOP 1) or 17 mm Hg or lower (target IOP 2) without antiglaucoma medications and qualified success as an IOP of 21 mm Hg or lower with or without medications. Maximal bleb thickness was measured using anterior segment optical coherence tomography images. RESULTS. The preoperative IOPs and numbers of preoperative antiglaucoma medications were similar for both groups. Complete target IOP 1 success rates were 38.1{\%} and 86.4{\%}, complete target IOP 2 success rates were 19.0{\%} and 59.1{\%}, and qualified success rates were 52.4{\%} and 90.9{\%} in the conventional and BAAVI groups, respectively (P = 0.05). The hypertensive phase rate was lower in the BAAVI group (4.5{\%} vs. 47.6{\%}, P = 0.002). Maximal bleb thickness was increased in the BAAVI group on postoperative days 30 and 180 (P = 0.05). CONCLUSIONS. Success rates were higher in the BAAVI group than in the conventional group with the change of bleb morphology. Furthermore, use of BCM significantly decreased the need for antiglaucoma medications for at least 6 months postoperatively.",
author = "Seungsoo Rho and Youngje Sung and Ma, {Kyoung Tak} and Rho, {Sae Heun} and Kim, {Chan Yun}",
year = "2015",
month = "1",
day = "1",
doi = "10.1167/iovs.15-17480",
language = "English",
volume = "56",
pages = "5896--5903",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "10",

}

Bleb analysis and short-term results of biodegradable collagen matrix-augmented ahmed glaucoma valve implantation : 6-month follow-up. / Rho, Seungsoo; Sung, Youngje; Ma, Kyoung Tak; Rho, Sae Heun; Kim, Chan Yun.

In: Investigative Ophthalmology and Visual Science, Vol. 56, No. 10, A023, 01.01.2015, p. 5896-5903.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bleb analysis and short-term results of biodegradable collagen matrix-augmented ahmed glaucoma valve implantation

T2 - 6-month follow-up

AU - Rho, Seungsoo

AU - Sung, Youngje

AU - Ma, Kyoung Tak

AU - Rho, Sae Heun

AU - Kim, Chan Yun

PY - 2015/1/1

Y1 - 2015/1/1

N2 - PURPOSE. To evaluate the short-term efficacy of a biodegradable collagen matrix (BCM) as an adjuvant for Ahmed valve implantation surgery to prevent the hypertensive phase. METHODS. This prospective study included 43 refractory glaucoma eyes, all followed for 6 months. Refractory glaucoma was defined as an IOP higher than 20 mm Hg with antiglaucoma eye drops without previous glaucoma surgery. Conventional method was performed in 21 eyes and BCM-augmented Ahmed valve implantation (BAAVI) in 22 eyes. In the BAAVI group, a 10 × 10 × 2-mm BCM was sutured on an Ahmed glaucoma valve FP7 model. Complete success was defined as an IOP of 21 mm Hg or lower (target IOP 1) or 17 mm Hg or lower (target IOP 2) without antiglaucoma medications and qualified success as an IOP of 21 mm Hg or lower with or without medications. Maximal bleb thickness was measured using anterior segment optical coherence tomography images. RESULTS. The preoperative IOPs and numbers of preoperative antiglaucoma medications were similar for both groups. Complete target IOP 1 success rates were 38.1% and 86.4%, complete target IOP 2 success rates were 19.0% and 59.1%, and qualified success rates were 52.4% and 90.9% in the conventional and BAAVI groups, respectively (P = 0.05). The hypertensive phase rate was lower in the BAAVI group (4.5% vs. 47.6%, P = 0.002). Maximal bleb thickness was increased in the BAAVI group on postoperative days 30 and 180 (P = 0.05). CONCLUSIONS. Success rates were higher in the BAAVI group than in the conventional group with the change of bleb morphology. Furthermore, use of BCM significantly decreased the need for antiglaucoma medications for at least 6 months postoperatively.

AB - PURPOSE. To evaluate the short-term efficacy of a biodegradable collagen matrix (BCM) as an adjuvant for Ahmed valve implantation surgery to prevent the hypertensive phase. METHODS. This prospective study included 43 refractory glaucoma eyes, all followed for 6 months. Refractory glaucoma was defined as an IOP higher than 20 mm Hg with antiglaucoma eye drops without previous glaucoma surgery. Conventional method was performed in 21 eyes and BCM-augmented Ahmed valve implantation (BAAVI) in 22 eyes. In the BAAVI group, a 10 × 10 × 2-mm BCM was sutured on an Ahmed glaucoma valve FP7 model. Complete success was defined as an IOP of 21 mm Hg or lower (target IOP 1) or 17 mm Hg or lower (target IOP 2) without antiglaucoma medications and qualified success as an IOP of 21 mm Hg or lower with or without medications. Maximal bleb thickness was measured using anterior segment optical coherence tomography images. RESULTS. The preoperative IOPs and numbers of preoperative antiglaucoma medications were similar for both groups. Complete target IOP 1 success rates were 38.1% and 86.4%, complete target IOP 2 success rates were 19.0% and 59.1%, and qualified success rates were 52.4% and 90.9% in the conventional and BAAVI groups, respectively (P = 0.05). The hypertensive phase rate was lower in the BAAVI group (4.5% vs. 47.6%, P = 0.002). Maximal bleb thickness was increased in the BAAVI group on postoperative days 30 and 180 (P = 0.05). CONCLUSIONS. Success rates were higher in the BAAVI group than in the conventional group with the change of bleb morphology. Furthermore, use of BCM significantly decreased the need for antiglaucoma medications for at least 6 months postoperatively.

UR - http://www.scopus.com/inward/record.url?scp=84941363475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941363475&partnerID=8YFLogxK

U2 - 10.1167/iovs.15-17480

DO - 10.1167/iovs.15-17480

M3 - Article

C2 - 26348639

AN - SCOPUS:84941363475

VL - 56

SP - 5896

EP - 5903

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 10

M1 - A023

ER -